Expert Consensus on Physician-Pharmacist Collaborative Management of Anti-IgE Monoclonal Antibody Treatment for Allergic Asthma
10.3870/j.issn.1004-0781.2025.08.001
- VernacularTitle:抗IgE单克隆抗体治疗过敏性哮喘的医药共管专家共识
- Collective Name:Subcommittee on Respiratory Diseases of the Division of Drug-Induced Diseases,Chinese Pharmacological Society;Guangdong Pharmaceutical Association;Allergy Branch of Guangdong Medical Association
- Publication Type:Journal Article
- Keywords:
Allergic asthma;
Physician-pharmacist collaborative management;
Anti-IgE monoclonal antibody;
Omalizumab
- From:
Herald of Medicine
2025;44(8):1185-1198
- CountryChina
- Language:Chinese
-
Abstract:
Objective To further standardize the rational use of anti-IgE monoclonal antibody treatment for allergic asthma.Methods Related issues in anti-IgE monoclonal antibody treatment management were identified through systematic reviews and clinical experience.A quality assessment was conducted using evidence grading system,and the Delphi method was employed to establish consensus recommendations,developed expert consensus on physician-pharmacist collaborative management of anti-IgE monoclonal antibody treatment for allergic asthma(referred to as the Consensus).Results The consensus,represented by the omalizumab,formulated 12 recommendations,encompassing the work model of physician-pharmacist collaborative management,clinical pathways,hierarchical diagnosis and treatment systems,and training and assessment.It provided a standardized management framework for physician-pharmaceutical collaborative management of omalizumab treatment in allergic asthma.Conclusion This consensus provides practical recommendations for pharmacists to engage in omalizumab treatment management,aiming to improve patients'medication compliance and disease prognosis,and optimize the clinical value of anti-IgE monoclonal antibody.
